Although many earlier studies did not demonstrate an overall survival benefit [60], a recently presented study at the San Antonio Breast Cancer Symposium reported a survival advantage associated with RRM in younger women (≤ 40 years) with breast cancer who carry a BRCA1/2 P/LP variant. This evidence concerns the gene BRCA1 and breast cancer.